Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single-Arm, Open-Label, Multi-Center Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy

NCT04498702 is registered in ClinicalTrials.gov with Jiangsu Yahong Meditech Co., Ltd aka Asieris as lead sponsor.

NCT NCT04498702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04498702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single-Arm, Open-Label, Multi-Center Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2014
Completion date
January 18, 2017
Enrollment
41 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer